CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 393 enrolled
Drug / intervention
Duloxetine 60 mg +1 moredrug
Likely dose
Duloxetine 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01552057
NCT01552057Phase 3Completed
CompareCT.gov

A Phase III Clinical Trial of Duloxetine in Participants With Fibromyalgia

Eli Lilly and Company·interventional·Posted Mar 13, 2012·Updated Jan 16, 2015

In Brief

A Phase 3 clinical trial evaluating Duloxetine 60 mg and Placebo for Fibromyalgia. Completed, enrolled 393 participants across 1 site.

Detailed Summary

The purpose of the study is to assess the effectiveness and safety of duloxetine in participants with fibromyalgia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFibromyalgia
CountriesJapan
CollaboratorsShionogi

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 13, 2012
Enrollment StartMar 1, 2012
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 14.3 years ago

Interventions

Duloxetine 60 mgdrug

Duloxetine 60 mg taken orally once every day for 15 weeks

Placebodrug

Placebo taken orally once every day for 15 weeks